CI, 1.65 7.27 ; P 0.01 were independent risk factors for target lesion revascularization TLR with SES. In contrast, no independent risk factors for restenosis and TLR were found for lesions treated with PES. The rate of TLR was signi cantly higher in patients on hemodialysis or in those with long lesions in the SES group hemodialysis, 30.4 vs. 11.1 , P 0.02 ; long lesions, 13.2 vs. 4.4 , P 0.01 ; for SES vs. PES, respectively . Rates of restenosis and TLR were signi cantly higher in patients with bent lesions in the SES group restenosis, 30.8 vs. 15.6 , P 0.01 ; TLR, 20.0 vs. 5.8 , P 0.01 ; for SES and PES, respectively . Most clinical studies have described better angiographic results for SES compared to PES. However, PES might result in better clinical outcomes than SES for patients on hemodialysis or for those with long or bent lesions.
Introduction
The introduction of drug eluting stents DES has remarkably improved the restenosis rate of percutaneous coronary intervention PCI . However, although DES have revolutionized PCI by signi cantly reducing the occurrence of restenosis and revascularization compared with bare metal stents during short-and long-term follow-up, restenosis and revascularization continue to occur in some patients treated with DES.
Sirolimus-eluting stents SES ; CYPHER Ⓡ ; Cordis Corporation / Johnson and Johnson, Miami Lakes, FL and paclitaxel-eluting stents PES ; TAXUS TM ; Boston Scienti c Corp., Natick, MA are the most studied DES to date. However, the bare metal stent platform, permanent polymer and the antiproliferative drugs signi cantly differ between SES and PES.
Sirolimus is an immunosuppressive drug with antiin ammatory properties that arrests the cell-cycle at the G1 / S phase transition, whereas paclitaxel is a cytotoxic, antineoplastic drug that causes cell-cycle arrest at the G2 / M phase transition 1, 2 . Sirolimus-eluting stents are based on the rigid and closed-cell, BX velocity Ⓡ , whereas PES are based on EXPRESS Ⓡ or LIBERTE Ⓡ that have a exible, open-cell design. Because these devices differ in terms of stent design and polymer construction, the question arises as to whether they differ with respect to implementation in PCI.
Diabetes mellitus [3] [4] [5] [6] , dialysis 7, 8 , long lesions and small vessels 9 , as well as chronic and total occlusion CTO 10-15 , have been described as risk factors for restenosis after PCI with bare metal stents. In contrast, risk factors for PCI using DES compared with bare metal stents have not been investigated in detail. A large multi-center study demonstrated similar DES efficacy profiles in patients with and without calcified coronary lesions. However, patients with severely calcified lesions were excluded from that trial 16, 17 . Therefore, we compared the clinical outcomes of PCI with SES and PES to determine independent risk factors for restenosis in such patients.
Methods

Study population
We analyzed data from 894 consecutive patients with coronary artery disease who were 
Angioplasty procedures
All angioplasties were performed using a 7-or 8-Fr guiding catheter and the femoral approach. Heparin was administered in boluses to achieve and maintain an activated clotting time of more than 250 s. Aspirin at least 100 mg for an inde nite period was administered immediately after the procedure and continued for as long as possible. Clopidogrel loading dose of 300 mg, followed by 75 mg / day for at least one year or ticlopidine loading dose of 200 mg, followed by 300 mg / day for at least one year was also started immediately after the procedure. Additional DES were used as necessary when dissection arose or lesions were not completely covered.
Stents were deployed with or without pre-dilation according to standard techniques and positioned to completely cover lesions. Dilation pressure was applied to the stent until the lesion was suf ciently dilated under transillumination. Intravascular ultrasound was used during all procedures to determine stent diameter pre-and post-dilation and after stenting to recon rm the position of the stent.
The lengths of SES and PES ranged from 13 33 mm and 12 33 mm, respectively, and diameters ranged from 2.5 4 mm and 2.25 3.5 mm, respectively. Aspirin and clopidogrel or ticlopidine were started immediately after stent implantation, as described above.
De nitions
Anginal symptoms were de ned according to the classi cation of the Canadian Cardiovascular Society. Major adverse cardiac events were de ned as death, myocardial infarction, or target lesion revascularization. Target restenosis was de ned as stenosis of ≥50 on follow-up coronary angiography. Target vessel revascularization was defined as clinicallydriven percutaneous revascularization or bypass of the target lesion or any segment of the epicardial coronary artery including the target lesion. Target lesion revascularization was de ned as any repeat revascularization procedure percutaneous or surgical at the original target lesion site. The primary endpoint was the occurrence of MACE during follow-up and independent predictors, which were compared between the groups. Calci ed lesions were de ned as identi able radiopaque images on still images obtained before injecting contrast agent or an identi able dark area on moving images. Lesions were de ned as being long if they were 20 mm in length, or being bent if they had a ≥45 bend at the center. Small vessel lesions were de ned as having a diameter of 2.75 mm. Procedural success was taken as thrombolysis in myocardial infarction ow 3 on nal images and a ≤25 residual rate of stenosis.
Quantitative coronary angiography
We used the QCA-CMS cardiovascular analysis system Medis Medical Imaging Systems, Raleigh, NC for coronary angiography. Lesion length, minimum vascular diameter and control vascular diameter were measured from dilation-phase frames taken from the same angle of minimal lesion contraction during pre-treatment, post-treatment and at remote-phase follow-up coronary angiography. Rates of stenosis, acquired inner diameter during the acute phase and the loss of inner diameter in the remote phase were calculated.
Statistical analysis
Quantitative data are presented as means SD, and categorical data as ratios . Data were statistically analyzed using the chi-square or Fisher s exact test two-tailed for categorical variables. Continuous variables were compared using the Student t test and P-values ≤0.05 were considered signi cant. Univariate and multivariate analyses, including 95 condence intervals CI , were calculated using logistic regression analysis. Factors with P-values 0.05 in the univariate analysis were entered into the multivariate model. All data were statistically analyzed using commercially available software Stat View for Windows version 5.0 .
Results
Base characteristics
The baseline characteristics of 462 and 432 patients who were treated with PCI using SES and PES, respectively, over a period of seven years are shown in Table 1 . Age, male sex, risk factors hypertension, dyslipidemia, hyperuricemia, current or previous smoking habit, hemodialysis, family history of cardiovascular disease, left ventricular ejection fraction and clinical presentation were similar in both groups.
Angiographic characteristics
The angiographic characteristics of the patients are shown in Table 2 . The rate of left main trunk and left anterior descending artery lesions was signi cantly higher in the SES 14.5 , than in the PES group 10.0 ; respectively, P 0.04 , while the rate of left anterior descending artery was signi cantly higher in the PES group 40.5 , than in the SES group 31.2 ; respectively, P 0.04 . 
Clinical outcomes
Data from the one-year clinical follow-up are shown in factors for TLR were found after treatment with PES.
Hemodialysis, long and bent lesions were risk factors for TLR in the SES group. The rates of restenosis and TLR in patients on hemodialysis are compared between the two groups, SES and PES, in Table 6 . The rates of restenosis in these patients were 32.1 n 18 and 20.0 n 9 in the SES and PES groups, respectively P 0.17 . The rates of TLR in these patients were 30.4 n 17 and 11.1 n 5 , for SES and PES, respectively P 0.02 . The rates of restenosis and TLR in patients with long lesions are compared between the SES and PES groups in Table 7 . The rates of restenosis in these patients were 22.3 for SES n 49 and 17.3 for PES n 43 ; P 0.18 and those of TLR were 13.2 n 29 and 4.4 n 11 , for SES and PES, respectively P 0.01 .
The rates of restenosis and TLR in patients with bent lesions are compared between the SES and PES groups in Table 8 . The rates of restenosis in these patients were 30.8 in the SES group n 37 and 15.6 in the PES group n 24 ; P 0.01 and those of TLR were 30.8 n 37 and 5.8 n 9 , in the SES and PES groups, respectively P 0.01 . 
Discussion
Various investigators have cited diabetes, hemodialysis, calci ed lesions, CTO, bent lesions, long lesions and vessel diameter as risk factors for restenosis after PCI with bare metal stents. However, independent clinical and angiographic risk factors for coronary restenosis after SES or PES implantation have never been reported as far as we can ascertain.
The rates of late loss are lower for SES than for PES. We also found no signi cant differences in late loss between SES and PES implantations, although SES was more frequently deployed than PES in small vessels and left main trunk lesions. In fact, the results of many randomized trials have indicated that SES can suppress neo-intimal hyperplasia more effectively then PES, and this results in a reduction of in-stent and in-segment late loss. However, this is not always associated with a reduction in binary restenosis, target vessel revascularization and MACE, as shown by the large randomized REALITY trial.18 On the other hand, some smaller randomized trials such as ISAR-SMART and SIRTAX have identi ed better angiographic or clinical parameters for SES than for PES 19, 20 .
Although most clinical comparisons of SES and PES have found better angiographic results for SES than PES, the two largest randomized stent trials and several smaller randomized controlled trials and registries have found equivalent clinical outcomes for the two types of stents [21] [22] [23] [24] . The present study found no differences between SES and PES in terms of clinical MACE, target lesion or vessel revascularization and restenosis, before and after adjustment for confounding factors in the setting of a routine practice. A meta-analysis of 16 randomized trials of SES versus PES in patients with coronary artery disease indicated that SES was more effective than PES in reducing the risk of re-intervention and stent thrombosis 25 . Another meta-analysis found a lower frequency of TLR within six months of SES deployment and of angiographic restenosis. However, these analyses included different study populations with variable follow-up durations and endpoint de nitions, which might limit the ability to reach a firm conclusion. The TAXi-LATE trial compared long-term 3-year clinical outcomes of stenting with SES versus PES. The ndings of that study supported previously published data indicating that both are equivalent in terms of treating coronary artery lesions 26 .
The present study uncovered signi cant differences in risk factors for restenosis and TLR between SES and PES. The risk factors for restenosis associated with SES were hemodialysis, as well as calci ed, long and bent lesions, and the latter two were independent risk factors for coronary restenosis. On the other hand, no risk factors were found for coronary restenosis in the PES group. Risk factors in the SES group for TLR were hemodialysis, calci ed, long and bent lesions. Independent risk factors for TLR in the SES group were hemodialysis, long and bent lesions, but no risk factors were associated with the PES group.
Stent design might have played a role in these differences, but whether or not the stent platform is directly involved in restenosis has not been reported. However, some studies angiographic characteristics did not signi cantly differ between the SES and PES groups, the selection of the stenting strategy was at the discretion of the operators. In addition, not all patients were followed up by coronary angiography and 12 months might not be a suf cient time to discern subsequent outcomes or the relationships identi ed in the present study.
Conclusion
Hemodialysis, and long and bent lesions were high risk factors for revascularization after PCI with SES. Rates of restenosis and TLR in the PES group did not signi cantly differ among these risk factors. The rate of TLR was signi cantly higher in patients with long or bent lesions or patients on hemodialysis in the SES group, than in the PES group. Most clinical studies comparing SES and PES have found better angiographic results for SES than PES. However, PES might result in better clinical outcomes than SES for patients on hemodialysis or for those with long or bent lesions. 
